Viral Infections Vaccines & Prevention Public Health

Hepatitis C elimination a 'political commitment challenge'

Share

Expanding access to prevention, diagnosis and curative treatment is essential to accelerate progress toward hepatitis C elimination, speakers said during the session "Global Elimination of Hepatitis C in 2026" at IDWeek 2026.  

“In my view, we have the tools to eliminate hepatitis C, so it's less and less a scientific challenge and more and more a political commitment challenge,” said John W. Ward, MD, director of the Coalition for Global Hepatitis Elimination at the Task Force for Global Health.  

Global progress falls short 

Dr. Ward cited World Health Organization estimates of approximately 47 million people with hepatitis C worldwide, about 20% fewer than the estimate for 2015. Global incidence had declined only about 8%, far short of the 90% reduction sought by 2030. He also reported an estimated 12% reduction in hepatitis C deaths since 2015, well short of the 65% reduction goal. 

Dr. Ward identified people who inject drugs and people who are incarcerated as two populations needing particular attention. He cited estimates suggesting that approximately one in four new hepatitis C infections worldwide among people who inject drugs occurs in the U.S. He also highlighted high prevalence and transmission in prisons and jails. 

He recommended combining counseling, sterile injection equipment, opioid substitution therapy, testing and treatment to reduce transmission among people who inject drugs. However, access remains limited: Dr. Ward said only a minority of countries provide needle and syringe programs and access to drug treatment, and few provide prevention services at levels considered protective.  

National programs nevertheless demonstrate progress, Dr. Ward said. Egypt reduced national prevalence from 10% to 0.4%. England expanded access through prescribing by nonspecialists, peer navigation, no patient copays and no treatment restrictions. Spain emphasized harm reduction, testing and treatment in correctional settings and simplified care pathways.  

England’s profile showed a 61% decline in general-population prevalence and an 18% decline in mortality from 2015 to 2024. From 2015 to 2023, Spain’s profile showed a 40% decline in general-population prevalence, a 53% decline in mortality and a 92% decline in prevalence among people who were incarcerated. 

Dr. Ward's central recommendation was to increase domestic financing, make hepatitis C elimination a health system priority and integrate testing and treatment into existing services. He also identified the cost of confirmatory virologic testing as a major barrier to expanding care. 

Specialists can close treatment gaps 

Norah Terrault, MD, MPH, professor of medicine at the University of Southern California, described a U.S. care gap: Approximately 68% of patients with hepatitis C have been diagnosed, and 43% of diagnosed patients have received treatment, compared with 2030 targets of 90% and 80%, respectively.  

She highlighted microelimination initiatives — focused elimination efforts within defined settings or populations — in health systems and hospitals as opportunities for specialists to expand treatment. She reported that the Veterans Affairs system had treated 80% of veterans with hepatitis C who were in care in 2021-2022, with sustained virologic response in more than 90% of those treated. Components included multidisciplinary teams, telehealth, expanded prescribing capacity, integrated substance use care, patient tracking and treatment financing. 

For hospital settings, Dr. Terrault shared the results of OPPORTUNI-C, a pragmatic, open-label, multicenter, stepped-wedge cluster randomized trial at three hospitals in Oslo, Norway. Treatment initiation within 6 months reached 85.7% with assessment and treatment during hospitalization or as soon as possible after discharge, compared with 46.1% with usual outpatient referral. The intervention combined liver disease staging, counseling, antiviral initiation and individualized follow-up. 

Emergency departments offer another entry point, although diagnosis alone does not ensure treatment, Dr. Terrault said. In DETECT Hep C, a pragmatic randomized trial at three urban emergency departments in Denver, Baltimore and Jackson, Mississippi, nontargeted screening resulted in a 34% higher rate of hepatitis C diagnosis than targeted screening. However, substantial losses occurred between diagnosis and linkage to care. She suggested that providing a full antiviral course from the emergency department could help address that gap. 

Dr. Terrault also advised treating acute hepatitis C upon confirmation of diagnosis, without waiting for spontaneous clearance. After cure, she emphasized lifelong liver cancer surveillance for patients who had cirrhosis before treatment. She also noted that metabolic dysfunction-associated steatotic liver disease was associated with an increased risk of liver complications after cure. 

Reaching populations with barriers to care 

Stacey B. Trooskin, MD, MPH, PhD, chief medical officer of Mazzoni Center, focused on pregnant people, children, people who use drugs, people who are incarcerated and men with HIV who have sex with men. She advocated integrated testing and treatment in settings patients already use, supported by telehealth, community partnerships and specialist consultation. 

Active substance use is not a contraindication to treatment, Dr. Trooskin emphasized. She reviewed HERO, a pragmatic randomized trial at 16 U.S. sites involving approximately 750 adults who inject drugs, which compared modified directly observed therapy with patient navigation. 

In the per-protocol analysis, sustained virologic response rates exceeded 90%; rates were lower in intention-to-treat analyses. A separate adherence analysis found response rates above 90% among participants with medication adherence as low as 50%. Dr. Trooskin urged clinicians to encourage completion of all prescribed medication while recognizing that imperfect adherence does not preclude cure. 

For correctional settings, Dr. Trooskin described recommendations for routine opt-out screening, treatment and linkage to care upon release. She also reviewed a Montreal modeling study that projected a 48% decline in incidence and prevention of 22% of new chronic infections with prison-based testing and treatment. Combining that strategy with risk reduction measures increased the projected proportion of new chronic infections prevented to 35%.  

Pregnancy and pediatric care present additional opportunities. Dr. Trooskin reported that hepatitis C infection among pregnant people increased from 1.8 to 5.1 per 1,000 live births in the U.S. between 2009 and 2019. She described nucleic acid testing for hepatitis C virus RNA in perinatally exposed infants at ages 2 to 6 months and treatment with an approved direct-acting antiviral regimen for children ages 3 and older with chronic infection. 

Dr. Trooskin said treatment during pregnancy is not universally recommended but can be considered individually after a clinician-patient discussion of potential risks and benefits. 

Approximately 7% of men with HIV who have sex with men have hepatitis C, according to Dr. Trooskin. She emphasized at least annual hepatitis C testing for sexually active adolescents and adults in this population. Dr. Trooskin also advocated combining screening with practical harm reduction—including condoms, lubricant and sterile injection equipment when applicable—and linkage to curative treatment to reduce onward transmission.  

Her broader recommendation was to integrate testing for HIV, hepatitis B, hepatitis C and sexually transmitted infections in one visit, then link patients to treatment or prevention according to their results. Prevention services included HIV pre-exposure prophylaxis, hepatitis A and B vaccination, sterile injection equipment, overdose prevention and sexual health services. 

Specialists can support this approach through telehealth, Project ECHO, community partnerships, mobile services and inpatient consultation, she said. “It really is about bringing the expertise that many of us have around treating hepatitis C to where the patients are and supporting the individuals who work there in various ways,” Dr. Trooskin said. 

Vaccines and a potential one-shot treatment

David Thomas, MD, MPH, of Johns Hopkins University School of Medicine, reviewed investigational tools to prevent infection and simplify treatment. He described evidence of immune protection after spontaneous clearance as a rationale for vaccine development, while emphasizing the disappointing results of a human vaccine trial. 

That double-blind, randomized, placebo-controlled phase 1/2 trial enrolled 548 adults ages 18 to 45 without hepatitis C who actively injected drugs. The T-cell vaccine produced immune responses and reduced peak viremia but did not reduce progression to chronic infection. 

Dr. Thomas suggested combining B-cell and T-cell approaches and using mRNA technology as possible research directions. He also discussed early work toward controlled human infection studies as a possible way to accelerate vaccine evaluation. 

For future treatment, Dr. Thomas presented preclinical work on an injectable, long-acting formulation of glecaprevir/pibrentasvir intended to provide a complete curative course in a single administration. In rats, he reported drug concentrations above the oral-treatment trough concentration benchmark at 8 weeks after injection. He said human testing is planned for 2027, involving 18 healthy volunteers for dose-ranging safety and pharmacokinetic assessments and six patients with hepatitis C for pharmacodynamic assessment.